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http://www.jbiomedsci.com/content/20/1/39RESEARCH Open AccessFlt-1 in colorectal cancer cells is required for the
tumor invasive effect of placental growth factor
through a p38-MMP9 pathway
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Background: Placenta growth factor (PlGF), a dimeric glycoprotein with 53% homology to VEGF, binds to VEGF
receptor-1 (Flt-1), but not to VEGF receptor-2 (Flk-1), and may function by modulating VEGF activity. We
previously have showed that PlGF displays prognostic value in colorectal cancer (CRC) but the mechanism
remains elucidated.
Results: Overexpression of PlGF increased the invasive/migration ability and decreased apoptosis in CRC cells
showing Flt-1 expression. Increased migration was associated with increasing MMP9 via p38 MAPK activation.
Tumors grew faster, larger; with higher vascularity from PlGF over-expression cells in xenograft assay. In two
independent human CRC tissue cohorts, PlGF, MMP9, and Flt-1 expressions were higher in the advanced than
the localized disease group. PlGF expression correlated with MMP9, and Flt-1 expression. CRC patients with high
PlGF and high Flt-1 expression in tissue had poor prognosis.
Conclusion: PlGF/Flt-1 signaling plays an important role in CRC progression, blocking PlGF/Flt-1 signaling
maybe an alternative therapy for CRC.
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Colorectal cancer (CRC) is the second leading cause of
death from cancer in Western countries [1] and the
third most common cancer in Taiwan [2]. The fact that
tumor growth and metastasis rely on angiogenesis has
been widely accepted [3]. Increased angiogenesis in the
primary tumor of CRC has been associated with poor
prognosis and relapse of disease [4,5]. Previously, we
have demonstrated that PlGF expression was up-
regulated in CRC tissue. Immunohistochemical staining
analysis showed that PlGF was expressed mainly in
tumor cells and Flt-1 was expressed in tumor cells as
well as in endothelial cells. The extent of up-regulation
correlated with disease progression and patient survival
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reproduction in any medium, provided the orserum placental growth factor levels were higher in CRC
patients and could be used as a prognostic indicator for
recurrence and survival of CRC [6]. However, the under-
lie mechanism of PlGF and its receptor (Flt-1) regulating
the CRC carcinogenesis remains unknown.
Placental growth factor (PlGF), a dimeric glycoprotein
with 53% homology to VEGF [7,8] binds to VEGF
receptor-1 (Flt-1), but not to VEGF receptor-2 (Flk-1),
and may function by modulating VEGF activity [9]. In
addition to the angiogenic effect, PlGF expression has
been reported in renal cell carcinomas, thyroid and
germ-cell tumors [10], as well as the meningiomas [11].
It also has been shown that in human gastric cancer,
breast, renal, and lung (non-small cell) cancer, PlGF was
over-expressed and displayed prognostic value [12-15].
In contrast to the expression of both Flk-1 and Flt-1 in
endothelial cells, Flt-1 is widely expressed in many non-
endothelial cell types, including hepatocytes, bone marrow
progenitor cells, monocytes, macrophages, neural cells,
vascular smooth muscle cells, and various tumor cells
[16-19]. Therefore, in addition to its role in angiogenesis,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biological functions, such as liver regeneration, inflam-
matory process and cancer metastasis [18,19].
Here we provide evidence that, in addition to the
angiogenesis, PlGF/Flt-1 signaling in colorectal cancer
cells can promote CRC invasion through a p38-MMP9
pathway and the association with the poor prognosis of




This study was approved by the Research Ethics
Committee of the National Taiwan University Hospital
(201107063RC).
Cell culture
Human 293 T cells and colon cancer cell lines SW480,
HCT116, HT29, and LoVo were obtained from the
American Type Culture Collection (ATCC, Manassas,
VA). They were cultured in DMEM with 10% fetal
bovine serum and 1% Penicillin/Streptomycin. Cells
were grown at 37°C in a 5% CO2 atmosphere within a
humidified incubator.
Human CRC tissue
Colorectal cryosections were prepared from colorectal can-
cer surgical samples which were collected from September
2000 to June 2003 after obtaining the written informed
consent, following the guidelines set forth by the Research
Ethics Committee of the National Taiwan University Hos-
pital. All tissues were freshly frozen or immersed in optimal
cutting temperature compound (OCT) (Ames Company,
Elkhart, IN), and kept at −80°C until use. Clinical staging of
cancers was determined based on the UICC-TNM classifi-
cation. Stages I and II were collectively termed the local-
ized disease group (n = 47) and stages III and IV as
advanced disease group (n = 33).
Reagents and antibodies
The p38 MAPK inhibitor SB203580 and the MMP9
inhibitor were purchased from Merck KGaA (Darmstadt,
Germany), and Zeocin from Invitrogen (Carlsbad, CA).
Polyclonal rabbit antibodies against phospho-JNK,
phospho-ERK 1/2, phospho-p38, and total JNK, ERK1/2,
and p38 were purchased from Cell Signaling Technology
(Danvers, MA). Other antibodies used were mouse
monoclonal antibodies to FLAG M2 (α-FLAG, Sigma
Chemical Co., St. Louis, MO), rat polyclonal anti-
CD31 (BD Biosciences, San Jose, CA), rabbit poly-
clonal anti-PlGF (C-20) (Santa Cruz, CA), anti-Factor
VIII (Biomeda Corporation, Foster, CA), anti-cleaved
Caspase-3 from Cell Signaling Technology (Danvers,
MA) and anti-MMP-9 (Abcam, Cambridge, UK).Recombinant PlGF was purchased from R&D Systems,
Inc. (Minneapolis, MN).
Plasmids, small interfering RNA, and transfection
The human PlGF expression vector was generated by
PCR amplification of full length of PlGF cDNA and
inserted into the multiple cloning site of pcDNA4/TO-
flag-strepII N1 Vector (Flag-StrepII tandem tag at the
N-terminus, derived from Invitrogen pcDNATM4/TO
vector). HA-tagged human Flt-1 expression vector,
pCMV-TAG-Flt-1 (HA-Flt-1), was generated by PCR
amplification of Flt-1 cDNA and insertion into the
multiple cloning sites of pCMV-TAG vector (Invitrogen,
Carlsbad, CA). Negative control siRNA, siFlt-1, sip38
(p38α), and siPlGF were purchased from Ambion Inc.
(Austin, TX). LoVo cells were transfected using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). For
generating the stable cell lines (LoVo, SW480, HT29
and HCT116), selection with Zeocin (100 μg/ml)
began one day after transfection and maintained under
same Zeocin condition.
RNA extraction and quantitative PCR
Total RNA from cell lines and tissue was isolated
using an RNA extraction kit (Qiagen Inc., Valencia,
CA), according to the manufacturer’s instructions. For
reverse transcription, 1 μg of total RNA was tran-
scribed using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). Quantitative PCR was performed in a
DNA Engine Opticon 2 (Bio-Rad, Hercules, CA) using iQ
SYBR Green supermix (Bio-Rad, Hercules, CA) with human
GAPDH as an internal control. Primers sequences used for







Cells were lysed with NP-40 lysis buffer and centrifuged
at 15,000 rpm for 20 minutes at 4°C. The supernatant
was assayed for protein concentration (Bradford). Equal
amounts of protein (150-250 μg/lane) was added to
Tris-Glycine SDS sample buffer (Invitrogen, Carlsbad,
CA) and separated on 4-12% gradient Tris-Glycine gels
(Invitrogen, Carlsbad, CA). Following electrophoresis,
proteins were electro-transferred to polyvinylidene
difluoride membranes and blocked with 5% bovine
serum albumin in TBST (Tris-Buffered Saline and
Tween 20). Membranes were then incubated with spe-
cific primary antibody overnight, washed, then incu-
bated with appropriate secondary antibody conjugated
to horseradish peroxidase, and developed using ECL
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and re-probed with anti-total MAPK (for MAPK anti-
bodies) or anti-actin to confirm equal protein loading.
Immunohistochemistry
Frozen sections (8 μm thick) were stained by using the
NoVo Link Polymer Detection System (Leica, Biosystems
Newcastle Ltd, UK), followed by AEC substrate kit
(Vector Laboratories Inc. Burlingame, CA), according to
the manufacturer’s instruction. Tissues were counter-
stained with Mayer’s hematoxylin. Isotype antibody was
used as the staining negative control.
ELISA (enzyme linked immunoabsorbent assay)
Concentrations of PlGF in cell culture medium were
quantified using a Quantikine PlGF immunoassay (R&D
Systems, Inc., Minneapolis, MN), as previously described
[2]. Concentrations of PlGF were expressed as pg/ml of
protein.
Apoptosis assay
Apoptosis was quantified by staining with the Annexin
V-FITC kit (Strong Biotech Corporation, Taipei, Taiwan),
data collection by flow cytometer (Becton Dickinson)
and analyzed by FlowJo 7.2 software. For tissue sections,
immunohistochemical staining with cleaved caspase 3
antibody was used for apoptosis analysis.
In vitro invasion and migration assay
The invasive activity of the cancer cells was examined
using a membrane invasion culture system in which a
polycarbonate membrane with 8-μm pores (Millipore.,
Billerica, MA) coated with Matrigel (R&D Systems, Inc.,
Minneapolis, MN) at 5 mg/mL was placed between the
upper and lower wells of a membrane invasion culture
system chamber. 5 × 104 cells were placed into each upper
well of the chamber. After incubating for 48 hours at
37°C, cells that had migrated through the coated mem-
brane were removed from the lower chamber with 1 mM
EDTA in PBS and dot blotted onto a polycarbonate mem-
brane with 3-μm pores. Blotted cells were stained with
Giemsa (Sigma Chemical Co., St. Louis, MO), and the
number of cells on each blot was counted under a micro-
scope at a magnification of × 50. Each experiment was
performed three times, and each sample was assayed in
triplicate. The migration assay was also performed using
the same procedure, except without the Matrigel coating.
Proliferation assay
Cell growth was measured using MTS [3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt] in the form of
the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay kit (Promega, UK), according to the manufacturer’sinstructions. Briefly, 1,500 cells/well were plated in 96 well
plates and allowed to proliferate for two days. The OD
490 correlated with cell density. All assays were repeated
thrice.Tumor xenograft growth assay
LoVo PlGF expression and mock (vector only) stable
cells in log phase were trypsinized and washed twice
with 137 mM NaCl, 5 mM KCl, 4 mM NaHCO3,
0.5 mM EDTA, 0.1% (w/v) glucose. 106 cells in 100 μl
PBS were injected subcutaneously into the backs of
8-week-old SCID mice. The body weight and tumor
size were recorded twice per week. After 14 weeks,
the mice were sacrificed. Tumor size was measured
and further studies were performed on the tissue.Microvessel density measurement
Using light microscopy at 200X magnification, the vas-
cular counts were measured for the tissue section
staining with CD31. The three areas with the highest
number of discrete microvessels were chosen for ana-
lysis and the region with the highest microvessel
counts was selected as the final result for that case
[20]. Any immunoreactive endothelial cells that were
separate from adjacent microvessels were considered
to be countable vessels.Gene expression dataset from the Gene Expression
Omnibus (GEO) database analysis.
The colorectal cancer patient gene expression data was avail-
able on Gene Expression Omnibus (GEO) with accession
number GSE17536. Expression data were analyzed using
GeneSpring GX software (Agilent Technologies). High and
low PlGF/Flt-1 expression was defined according to the me-
dian expression level in each group.Statistical analysis
Statistical differences between groups were analyzed by
Student’s t test or Mann–Whitney U test. Data was
expressed as means ± standard errors (SE). Correlations
between PlGF and MMP-9 expression levels were ana-
lyzed by Spearman’s correlation coefficient. A p value of
0.05 was considered to be statistically significant. The
body weight difference along with the time between the
LoVo-PlGF and control group, in terms of group effect,
time effect, and their interactive effect, were analyzed
using the mixed model. Based on fit statistics for Akaike
information criterion (AIC) and Bayesian information
criterion (BIC) criteria, the repeated measures were
modeled using the first-order ante dependence for the
covariance structure [21].
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Expression of PlGF and its receptor Flt-1 in CRC cell lines
When we arbitrarily used SW480 expression as 1, Flt-1
expression in LoVo cells was 7.4, and 5971 for the Flt-
1 overexpression in 293 T cells; Flt-1 was not detect-
able in the negative control and barely detectable in
both HT29 and HCT116 cell lines (Figure 1A). In con-
trast, PlGF was expressed (within folds of change) in
the four CRC cell lines (Figure 1B) by quantitative
PCR.
Flt-1 is required for PlGF-induced invasive/migration
ability of CRC cells exogenously added PlGF or
overexpression of PlGF increased the invasive/migration
ability of CRC cells expressing Flt-1
Exogenous PlGF significantly increased the invasive
ability of LoVo cells, which expressed the highest Flt-1
levels of the cell lines tested by up to four fold. Con-
versely, HT29 and HCT116, cell lines in which Flt-1 was
virtually undetectable, did not respond to exogenously
added PlGF (Figure 1C). To further confirm the role of
PlGF in CRC cancer cells, we generated the PlGF-over-
expression stable clones in LoVo, SW480, HT29 and
HCT116 cells as well as their empty vector control cells.
The over-expression of PlGF in these stable clones have
been validated and monitored periodically by quantita-
tive PCR, which we got hundreds of fold increased ex-
pression of PlGF than the control cell lines. Migration
assay was performed to compare the stable clones with
and without PlGF and normalized to the empty vector
control. Migration ability increased in LoVo and SW480
with stable expression of PlGF, but no change in HT29
cells and even decreased in HCT116 cells (Figure 1D).
This data suggests that Flt-1 receptor may be critical for
PlGF induced tumor cell invasion in CRC cells.
Overexpression of PlGF in CRC cells mildly decreased
apoptosis, but did not affect their proliferative status
Stable clones have been validated for the presence of
the transgene and for overexpression of PlGF protein
by quantitative RT-PCR, Western blot and ELISA
(Figure 1E, F and G). According to the datasheet, it
showed PlGF (C-20) can be used for detecting variants
of PlGF of human origin. The overexpressed PlGF was
double confirmed by immunoblotting with Flag and
PlGF. As increased invasion/migration was shown
most prominently with the LoVo stable clone for
PlGF, LoVo-PlGF and its control LoVo-pcDNA were
used for the following experiments. The migration and
invasion abilities increased 4.9 and 3.9 fold in LoVo-
PlGF cells as compared to LoVo-pcDNA, respectively
(Figure 1H, I). There was minor apoptosis difference
by PI and annexin V staining between LoVo-pcDNA
and LoVo-PlGF cells, 3.2% and 1.3%, respectively, andno difference in the proliferation status by MTS assay
between these two cell lines (data not shown).
The increased migration ability of LoVo-PlGF cells is
through increasing MMP9 expression via p38 MAPK
activation
In LoVo cells with overexpression of PlGF, we found that
phosphorylation of p38 increased but there was no in-
crease in the phosphorylation levels of ERK and JNK
MAP kinases (Figure 2A). It might be due to the exposure
time which showing the phospho-ERK at both pcDNA
and PlGF group. From the results, we could say there was
no significant difference between the pcDNA and PlGF
group for the expression of ERK (both phospho and total
form). Inhibition of p38, either by using p38 chemical
inhibitors (Figure 2B) or siRNA (Figure 2C), decreased the
ability of LoVo-PlGF cells to migrate. All experiments had
been performed at least 3 times.
Several lines of evidence have shown that p38 acti-
vation is required for MMP9 expression, which has
been linked to tumor migration and invasion [22,23].
We therefore checked MMP9 expression in LoVo-
PlGF cells. Indeed, MMP9 expression was significantly
increased in LoVo-PlGF cells compared to control at
the message level (Figure 3A), and inhibition of p38
by both siRNA and chemical inhibition both decreased
the expression of MMP9 at the protein level (Figure 3B
and data not shown). The migration ability was inhi-
bited by using the chemical inhibitor of MMP9
(Figure 3C).
To investigate the clinical significance of this in vitro
finding, we checked PlGF, Flt-1, and MMP9 expression
in 80 human colorectal cancer tissues at the message
level. We found, indeed, PlGF, MMP9, and Flt-1 expres-
sion were significantly higher in the advanced CRC
group than the localized CRC group (Figure 3D, E and
F). Moreover, the expression of MMP9 in human CRC
tumor samples significantly correlated with the PlGF
expression levels in the samples (Figure 3G), as well as
the PlGF expression and Flt-1 expression (Figure 3H).
Flt-1 is required for PlGF-induced p38 phosphorylation and
its results of promoting CRC cells migration/invasion.
Next, we asked whether Flt-1 expression is required for
PlGF-induced tumor invasion since only the Flt-1 ex-
pressing CRC cell line responded to exogenous PlGF. To
address this question we used a siRNA approach to in-
hibit Flt-1 expression in LoVo-PlGF cells (Figure 4A).
We have tried the Western blot for Flt-1, however, we
could only detect the over-expressed one but not the en-
dogenous one. This may be due to the low expression
level of endogenous Flt-1. Therefore, we could only
show the data by quantitative PCR. The migration ability
decreased when Flt-1 levels were reduced by siRNA
Figure 1 Expression and biological function of PlGF and Flt-1 in CRC cell lines. Quantitative PCR levels of Flt-1 (A) and PlGF (B) in CRC cell
lines. The expression of SW480 was arbitrarily defined as the reference for comparison. (C) PlGF recombinant protein (10 ng/ml) increased the
invasion ability in LoVo but not HT29 and HCT116 cells; (D) stable overexpression of PlGF increased the migration ability in LoVo and SW480 cells,
but not in HT29 and HCT116 cells. PlGF level in the LoVo-PlGF (PlGF overexpressioin) cells was validated by quantitative RT-PCR (E), Western blot
(F) (anti-PlGF at 200 ng/ml) and ELISA (G). The migration (H) and invasion (I) abilities increased in LoVo-PlGF cells as compared to LoVo-pcDNA,
respectively. (Neg: negative control; Pos; positive control. * indicated as P < 0.05).
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induced CRC cell migration. To further confirm this
result, we checked the effect of siFlt-1 on p38 phospho-
rylation in LoVo-PlGF cells. Indeed, downregulation ofFlt-1 significantly attenuated the phosphorylation of p38
in LoVo-PlGF cells (Figure 4C). We also found that
both migration and invasion ability decreased in LoVo-
PlGF cells when the PlGF was knocked down
Figure 2 Increased migration of LoVo-PlGF cells was due to increasing p38 MAPK activation. (A) Phosphorylation levels of p38, JNK
and ERK are shown along with total protein levels of p38, JNK and ERK in LoVo-PlGF and LoVo pcDNA control cells. (B) Inhibition of p38
by chemical inhibitor, SB203580 (20 μM) as well as by siRNA of p38 (30 pmole/ml) (C), decreased the migratory ability of LoVo-PlGF.
* indicated as P < 0.05.
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(Figure 4E).
Tumor progression was enhanced in LoVo-PlGF cells ex vivo
To confirm the role of PlGF in CRC ex vivo, tumor
xenograft assays were performed. During the observa-
tion period, three of the four LoVo-PlGF cells im-
planted mice had palpable nodules as early as the 3rd
week, and all of them had measurable tumors by the
end of the 14 week experimental period. In contrast,
only two of the four mice in the LoVo-pcDNA group
had palpable nodules, detectable only in the 10th
week (Figure 5A). The LoVo-PlGF group also gained
weight slower than the control group (Figure 5B,
group effect, P = 0.0137). The body weight difference
became even more significant during follow-up(interactive effect between time and group; P < 0.0001).
Mice were sacrificed following week 14. Both the
tumor radius and tumor volumes were larger in the
LoVo-PlGF group (Figure 5C and D). PlGF expression
was indeed significantly higher in the tumor tissue
induced by LoVo-PlGF cell implantation (Figure 5E).
LoVo-PlGF induced tumors had higher vascularity
(Figure 5F), higher microvessel density (Figure 5G),
and less caspase 3 staining (Figure 5H) than the
control group.
High expression of PlGF and Flt-1 in CRC tissues predicts
worse prognosis
We further analyzed a publicly available gene expression
dataset from the GEO database. In this cohort, higher
PlGF and Flt-1 mRNA expressions were observed in
Figure 3 PlGF induced MMP9 expression via p38 MAPK activation. (A) MMP9 expression was significantly increased in LoVo-PlGF cells
compared to LoVo-pcDNA cells as assessed by quantitative PCR. (B) Inhibition of p38 by siRNA (30 pmole/ml) decreased the expression of MMP9
in LoVo-PlGF cells as detected by Western blotting. (C) By using the chemical inhibitor of MMP9 (30 μM), the migration ability was inhibited in
LoVo-PlGF cells. In human colorectal cancer tissue, PlGF (D), MMP9 (E) and Flt-1 (F) expression were significantly higher in the advanced than
localized disease group. There was a strongly positive correlation between the expression of PlGF and MMP9 (G), as well as PlGF and Flt-1
(H). * indicated as P < 0.05.
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stage I-II disease (localized disease) (Figure 6A and B).
Patients that had high Flt-1 and high PlGF expression
had shorter survival (p = 0.016) (Figure 6C). Flt-1 expres-
sion was correlated with PlGF (p = 0.003, correlation
coefficient: 0.225) (Figure 6D). This result supports the
in vitro study results, validating the results from NTUH
cohorts, and strongly implies that high PlGF levelscombined with high Flt-1 expression increase cancer in-
vasion and lead to shorter survival.
Discussion
In this study we demonstrated that CRC cells express
PlGF and Flt-1 have higher invasion/migration ability.
PlGF increased the invasion/migration ability of colorec-
tal cancer cells by increasing the phosphorylation of p38
Figure 4 Flt-1 is required for PlGF-induced p38 phosphorylation, PlGF and Flt-1 were both important in promoting CRC cancer cell
migration/invasion. siRNA (30 pmole/ml) inhibited Flt-1 expression and migratory ability in LoVo-PlGF cells as monitored by quantitative PCR (A)
and migration assay (B). (C) Knockdown Flt-1 significantly attenuated p38 phopsphorylation in LoVo-PlGF. (D, E). The invasion ability of CRC cells
decreased when PlGF was inhibited by siRNA. * indicated as P < 0.05.
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of PlGF decreased the apoptosis mildly, but did not affect
the cell proliferation status. These in vitro results had been
validated by using two independent CRC cohorts and
showed that patients with high PlGF and high Flt-1 expres-
sion in CRC tissue had a poorer prognosis. These results re-
vealed that, in addition to previously recognized effects on
angiogenesis, PlGF also plays a hitherto unappreciated
role in CRC carcinogenesis.
How the PlGF regulates CRC carcinogenesis? PlGF
has been shown to increase tumor cell migration in lung
cancer, leukemic and melanoma cells [24-26]. It also has
been shown that the increased migration of leukemic
cells was via the p38/ERK pathway resulting in Rho
GTPases activation and caveolae formation [24]. In
addition, Loesch et al. demonstrated that the p38gamma
MAPK cooperated with transcription factor c-Jun intrans-activating MMP9 which resulted in cell invasion
[27]. In line with these findings, our data linked the
over-expression of PlGF with the upregulation of MMP9
expression by increasing phosphorylation of p38 MAPK
in colorectal cancer cells. In addition, knockdown of p38
MAPK, either by chemical inhibition or siRNA, de-
creased the expression of MMP9 and the ability of
tumor cells to migrate. Furthermore, PlGF expression
levels in human CRC tissues correlated well with their
MMP9 expression. Taken together, these data suggest
that in colorectal cancer cells, PlGF induces tumor cell
invasion and migration through upregulation of MMP9
expression by increasing p38 phosphorylation.
Flt-1, one of the well studied receptors of both PlGF
and VEGF, plays an important role in regulating
vasculogenesis and angiogenesis [28,29]. In addition to
angiogenesis, the VEGF-Flt-1 connection also plays an
Figure 5 (See legend on next page.)
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Figure 5 Tumors grew faster and larger in animals receiving LoVo-PlGF xenografts. (A) At the 10th week after injection, tumors were
visible in the LoVo-PlGF group but not in the LoVo-pcDNA group. (B) The LoVo-PlGF group lagged behind in body weight gain. Both the tumor
radius (C) and tumor volumes (D) were larger in the LoVo-PlGF group than the control group. (E) PlGF expression was significantly higher in the
tumor tissue induced by LoVo-PlGF cells. (F) Angiogenesis was also more advanced in the LoVo-PlGF group, with the microvessel density shown
in (G). (H) Less apoptosis in LoVo-PlGF group than the control group. * indicated as P < 0.05.
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monocytes/macrophages and inducing their migration
[16,17,30,31]. Previously, Xu et al. reported that
overexpression of PlGF in HCT116 cells decreased tumor
growth, cancer cell invasion and angiogenesis [32]. This
result appears to contradict our findings and the clinical
observations of others that higher expression of PlGFFigure 6 PlGF correlated with Flt-1 expression in CRC tissue and patie
prognosis in another CRC cohort. (A, B) higher Flt-1 and PlGF mRNA exp
compared to stage I-II disease (localized disease). (C) Patients with high Flt-
correlated well with PlGF levels.correlates with poor prognosis [2,6,11-15,33,34]. To eluci-
date this discrepancy, we checked the PlGF major receptor-
Flt-1 status of four different colorectal cancer cell lines, and
found that Flt-1 was barely detectable in both HCT116 and
HT29 cell lines. In fact, we found exogenous PlGF recom-
binant protein or stable overexpression of PlGF led to in-
creased invasive ability only in cells with Flt-1 expression.nts with higher expression of PlGF and Flt-1 had worse
ressions were observed in stage III-IV disease (advanced disease)
1 and high PlGF expression had shorter survival. (D) Flt-1 expression
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cells depending upon whether the Flt-1 receptor is present,
though the role of PlGF in tumor angiogenesis remains
controversial [35,36].
Flt-1 protein contains two isoforms, one is the trans-
membrane receptor (mFlt-1) and the other is the soluble
isoform (sFlt-1). sFlt1 is antiangiogenic as it can function
as a decoy that traps the VEGF and PlGF, then prevents
binding to VEGFR; whereas mFlt1 is proangiogenic
[37,38]. Our results demonstrated that high Flt-1 expres-
sion in colorectal cancer cells increased their invasive
ability, and is associated with poor prognosis. Recently,
Yao et al. also found this similar condition and reported
that the role of PlGF in tumorigenesis largely consists of
promoting autocrine/paracrine growth of tumor cells ex-
pressing a functional Flt-1 rather than stimulation of
angiogenesis [39].
Conclusion
In addition to the well known effect on angiogenesis,
PlGF/Flt-1 signaling plays a previously unappreciated
important role in colorectal carcinogenesis by increasing
the phosphorylation of p38 MAPK, thereby upregulating
MMP9 expression; resulting in increasing cellular migra-
tion/invasion. Blocking PlGF-Flt-1signaling may be an
alternative therapy for treating CRC.
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